Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Jason Bielas
Fred Hutchinson Cancer Research Center, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Grail, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Bielas is an inventor of certain deep sequencing technology (“CypherSeq”) that has been licensed by the Institution to Grail. As a result, Dr. Bielas is entitled to a share of royalties and equity. This project will utilize CypherSeq to sequence the mtDNA genome to resolve the landscape of mtDNA mutagenesis in breast cancer, and possibly identify other regions of the mitochondrial genome where mutation accumulation predicts pathological complete response in response to neoadjuvant chemotherapy in locally advanced breast cancer. The outcome of this project could impact the utility and value of the Cypher Seq technology, which in turn could impact the value of Dr. Bielas’ ownership and intellectual property interests in Grail.
Delineating the mechanisms and clinical utility of mtDNA mutagenesis in cancer
Despite the mitochondrion?s well-known roles in metabolism and cell death, mitochondrial-targeted therapies have yet to be exploited to improve cancer therapies. We propose to leverage and expand upon our recent discoveries in mitochondrial tumor biology to i) develop better predictors of a cancer patient?s treatment response to guide clinicians and patients toward the best course of personalized therapy, and ii) transform the treatment of cancer by replacing therapies that have life-threatening toxicities with ones that are safe and effective.
Filed on March 28, 2017.
Tell us what you know about Jason Bielas's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Jason Bielas filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Jason Bielas | Fred Hutchinson Cancer Research Center | Conflict of Interest | Grail, Inc. | $80,000 - $99,999 |
| Jason Bielas | Fred Hutchinson Cancer Research Center | Conflict of Interest | Grail, Inc. | $80,000 - $99,999 |
| Jason Bielas | Fred Hutchinson Cancer Research Center | Conflict of Interest | Grail, Inc | $80,000 - $99,999 |
| Jason Bielas | Fred Hutchinson Cancer Research Center | Conflict of Interest | Grail, Inc. | $80,000 - $99,999 |
| Jason Bielas | Fred Hutchinson Cancer Research Center | Conflict of Interest | Grail, Inc. | $80,000 - $99,999 |
| Jason Bielas | Fred Hutchinson Cancer Research Center | Conflict of Interest | Grail, Inc | Value cannot be readily determined |
| Jason Bielas | Fred Hutchinson Cancer Research Center | Conflict of Interest | Grail, Inc. | Value cannot be readily determined |
| Jason Bielas | Fred Hutchinson Cancer Research Center | Conflict of Interest | Grail, Inc | Value cannot be readily determined |
| Jason Bielas | Fred Hutchinson Cancer Research Center | Conflict of Interest | Grail, Inc. | Value cannot be readily determined |
| Jason Bielas | Fred Hutchinson Cancer Research Center | Conflict of Interest | Grail, Inc. | Value cannot be readily determined |
| Jason Bielas | Fred Hutchinson Cancer Research Center | Conflict of Interest | Grail, Inc. | Value cannot be readily determined |
| Jason Bielas | Fred Hutchinson Cancer Research Center | Conflict of Interest | Grail, Inc. | Value cannot be readily determined |
| Jason Bielas | Fred Hutchinson Cancer Research Center | Conflict of Interest | Grail, Inc. | Value cannot be readily determined |
| Jason Bielas | Fred Hutchinson Cancer Research Center | Conflict of Interest | Grail, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.